tiprankstipranks
Trending News
More News >
Allovir Inc (ALVR)
NASDAQ:ALVR
US Market

AlloVir (ALVR) AI Stock Analysis

Compare
342 Followers

Top Page

AL

AlloVir

(NASDAQ:ALVR)

Rating:41Neutral
Price Target:
AlloVir's overall stock score is primarily constrained by its challenging financial performance, characterized by ongoing losses and lack of revenue. The recent merger with Kalaris Therapeutics offers a positive outlook due to the cash infusion and potential for strategic growth. However, the technical indicators show neutral momentum, and the valuation is weak due to the absence of earnings. These factors collectively result in a below-average stock score.

AlloVir (ALVR) vs. SPDR S&P 500 ETF (SPY)

AlloVir Business Overview & Revenue Model

Company DescriptionAlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
How the Company Makes MoneyAlloVir makes money primarily through the development and commercialization of its proprietary T cell therapies. The company's revenue model focuses on the successful progression of its clinical trials and eventual regulatory approval, allowing for the marketing and sale of its therapies. Key revenue streams include potential milestone payments and royalties from partnerships with pharmaceutical companies and healthcare providers. AlloVir's earnings are significantly influenced by its ability to advance its clinical pipeline and secure strategic collaborations to support its research and development efforts.

AlloVir Financial Statement Overview

Summary
AlloVir faces significant financial challenges typical of biotech firms in the development phase. The absence of revenue underscores reliance on external funding to sustain operations. While the company has managed to maintain a strong cash position, the ongoing net losses and negative cash flows highlight the need for breakthroughs in product development or revenue generation to achieve financial sustainability.
Income Statement
5
Very Negative
AlloVir's income statement shows consistent challenges with revenue generation, as the company reported no revenue in the latest periods. This has led to substantial net losses, reflecting the ongoing high costs without offsetting income. The company’s EBIT and EBITDA margins are negative, indicating a significant challenge in managing operational expenses efficiently.
Balance Sheet
40
Negative
The balance sheet reflects a relatively strong equity position with no debt as of the latest report, which is positive. However, the consistent net losses have eroded equity over time. The company’s equity ratio is relatively healthy, indicating a strong reliance on equity financing rather than debt, which reduces financial risk in the near term.
Cash Flow
30
Negative
AlloVir's cash flow statement highlights significant operational cash outflows, reflecting the ongoing operational costs without revenue support. The free cash flow is negative, indicating reliance on external financing or cash reserves for sustainability. However, cash flow from financing activities has helped bolster cash reserves.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit0.00-398.00K-2.56M-1.12M-73.00K
EBITDA-65.44M-190.15M-166.41M-169.84M-69.71M
Net Income-58.77M-190.42M-168.71M-171.96M-68.38M
Balance Sheet
Total Assets118.55M190.80M277.08M286.59M370.82M
Cash, Cash Equivalents and Short-Term Investments118.29M183.94M233.79M248.12M356.32M
Total Debt0.0027.43M35.39M30.07M8.69M
Total Liabilities5.24M45.02M52.56M61.33M17.76M
Stockholders Equity113.31M145.78M224.52M225.27M353.06M
Cash Flow
Free Cash Flow-67.70M-124.45M-141.95M-106.34M-61.05M
Operating Cash Flow-67.70M-124.45M-142.05M-106.32M-60.81M
Investing Cash Flow95.00M37.98M-80.48M185.98M-169.50M
Financing Cash Flow21.00K70.50M126.96M232.00K291.98M

AlloVir Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥343.99B10.56-2.88%2.55%11.80%-6.84%
51
Neutral
$48.67M-546.55%127.51%56.94%
48
Neutral
$581.05M-51.85%11070.12%32.07%
47
Neutral
$132.74M-262.12%239.92%79.41%
46
Neutral
$130.68M-49.23%105.85%22.13%
41
Neutral
$30.20M-45.37%72.12%
41
Neutral
$63.17M-273.36%883.05%62.93%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ALVR
AlloVir
9.21
-7.69
-45.50%
SGMO
Sangamo Biosciences
0.54
0.22
68.75%
BLUE
Bluebird Bio
4.97
-13.32
-72.83%
FATE
Fate Therapeutics
1.14
-2.02
-63.92%
IOVA
Iovance Biotherapeutics
1.74
-5.65
-76.45%
ADAP
Adaptimmune Therapeutics
0.23
-0.79
-77.45%

AlloVir Corporate Events

M&A TransactionsBusiness Operations and Strategy
AlloVir Merges with Kalaris Therapeutics, Inc.
Positive
Mar 18, 2025

On March 18, 2025, Kalaris Therapeutics, Inc. announced the completion of its merger with AlloVir, Inc., resulting in a combined company that will operate under the name Kalaris Therapeutics, Inc. and trade on Nasdaq under the ticker symbol ‘KLRS’ starting March 19, 2025. The merger has led to a change in the company’s stock ownership structure, with Legacy Kalaris stockholders owning approximately 74.47% and AlloVir stockholders owning about 25.53% of the combined company’s outstanding common stock. The merger is expected to provide Kalaris with approximately $100 million in cash, which will fund its operations into the fourth quarter of 2026, supporting the continued development of its lead product candidate, TH103, which is currently in a Phase 1 clinical trial.

M&A TransactionsShareholder Meetings
AlloVir Stockholders Approve Key Amendment and Merger
Neutral
Mar 12, 2025

On March 12, 2025, AlloVir held a special meeting where stockholders approved an amendment to the 2020 Stock Option and Grant Plan, increasing the number of shares available for future issuance and extending the plan’s term. The approval of this amendment and the merger with Kalaris, which involves a change of control and issuance of new shares, is expected to impact AlloVir’s operations by expanding its capital base and potentially enhancing its market position, although there are inherent risks and uncertainties associated with the merger.

Executive/Board Changes
AlloVir Appoints Vikas Sinha as New CEO
Neutral
Dec 20, 2024

AlloVir, Inc. announced that Dr. Diana Brainard has stepped down as Chief Executive Officer and director, with Vikas Sinha taking over as CEO effective December 19, 2024. Sinha, who has extensive experience in executive finance roles within the life sciences industry, is expected to lead the company following the departure of Dr. Brainard, who left with a comprehensive severance package.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―